Skip to main content
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. — Investor Relations & Filings

Ticker · VIR ISIN · US92764N1028 US Manufacturing
Filings indexed 727 across all filing types
Latest filing 2021-05-21 Director's Dealing
Country US United States of America
Listing US VIR

About Vir Biotechnology, Inc.

https://www.vir.bio/

Vir Biotechnology, Inc. is a clinical-stage immunology company that leverages the immune system to treat and prevent serious infectious diseases and other conditions. The company's pipeline is built on two primary technology platforms: a next-generation antibody platform for identifying and optimizing therapeutic candidates, and the PRO-XTEN® protease-releasable masking technology for applications in oncology. Vir's main therapeutic area is infectious diseases, featuring a leading program for chronic hepatitis delta, and is complemented by strategic programs in oncology. The company has demonstrated its capabilities by developing antibody-based medicines for significant health challenges, including COVID-19 and Ebola.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-05-21 English
FORM 4 SUBMISSION
Director's Dealing
2021-05-21 English
FORM 4 SUBMISSION
Director's Dealing
2021-05-19 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 6, 2021, reporting the issuance of a press release announcing financial results for the quarter ended March 31, 2021. The text states that the press release is attached as Exhibit 99.1 and is incorporated by reference. The document itself does not contain the financial results but rather announces their release. The length is 3525 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (the earnings release) rather than the report itself. Therefore, the appropriate classification is Earnings Release (ER).
2021-05-06 English
10-Q
Interim / Quarterly Report Q1 2021
2021-05-06 English
FORM 4 SUBMISSION
Director's Dealing
2021-05-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.